SYMQY Company Profile and Key Details

SymBio Pharmaceuticals Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.15. This means the shares are trading below this model’s fair value.

SymBio Pharmaceuticals Limited trades at a P/E ratio of -0.84, slightly below the S&P 500 average, with a price-to-sales ratio of 3.67 and a price-to-book ratio of -11.71 indicating negative book value, which may reflect financial stress. The P/FCF stands at 0.0, also below market averages.

Our AI price prediction model suggests that SymBio Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows SymBio Pharmaceuticals Limited trading at a premium to the broader market with a P/E of -0.84.

The stock is currently trading near its 52-week low $0.56 and $1.19. With a market capitalization of about $26.38 million, SymBio Pharmaceuticals Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 134.00 shares, volume is running light vs its 52-week average. Headquartered in Tokyo, TY, SymBio Pharmaceuticals Limited operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Fuminori Yoshida, the company employs approximately 91 people and listed since August 05, 2016. SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business.